Climb Bio Completes Transition To Immune-mediated Disease Focused Company; Expects Cash Runway Through 2027 To Enable Delivery Of Key Value Inflection Points

BenzingaOct 15 19:44

Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event

GlobeNewswireOct 15 19:00

Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024

GlobeNewswireOct 12 00:30

Climb Bio to Present at William Blair's Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19

GlobeNewswireOct 4 19:00

News On Eliem Therapeutics Inc. (ELYM) Now Under CLYM

Dow JonesOct 4 05:08

Climb Bio to Host Virtual Investor Event on October 15, 2024

GlobeNewswireOct 3 22:00